{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:06:36Z","timestamp":1783958796914,"version":"3.55.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Evaluating the safety of selective serotonin reuptake inhibitors (SSRIs) during pregnancy is challenging due to ethical barriers to randomized trials and potential confounding in observational studies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare neonatal outcomes for pregnancies with SSRI continuation vs those with SSRI discontinuation using a target trial framework.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study comprised target trials using electronic health records of linked mothers and neonates from a single academic center. The periconception trial examined congenital anomalies with first-trimester exposure, and the early-pregnancy trial evaluated nonanomaly outcomes with first- or second-trimester exposure. Participants were women with singleton pregnancies (2006 to 2022) with SSRI use within the 2 years before conception and at least 1 prenatal visit during the first trimester (periconception trial) or during the first or second trimester (early-pregnancy trial). Data were analyzed from May 2022 to December 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n SSRI continuation vs discontinuation during pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Apgar scores, meconium in amniotic fluid, neonatal intensive care unit (NICU) admission, preterm birth, birth weight, respiratory distress, feeding problems, hypoglycemia, hypothermia, pulmonary hypertension, cesarean delivery, and congenital anomalies.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The early-pregnancy trial included 1014 pregnancies (mean [SD] maternal age, 30.3 [5.4] years). The periconception trial included 807 pregnancies (mean [SD] maternal age, 30.4 [5.5] years). SSRI continuation was associated with lower Apgar scores at 1 minute (mean difference [MD], \u20130.39; 95% CI, \u20130.60 to \u20130.18) and 5 minutes (MD, \u20130.28; 95% CI, \u20130.42 to \u20130.13), and increased risk of meconium in amniotic fluid (odds ratio [OR], 1.73; 95% CI, 1.22 to 2.45). No significant associations were found for congenital anomalies (OR, 1.09; 95% CI, 0.63 to 1.90), though this result should be interpreted with caution given limited sample size. No differences were found for neonatal intensive care unit admission (OR, 1.23; 95% CI, 0.82 to 1.83) or other outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, SSRI continuation during pregnancy was associated with impaired neonatal adaptation but not with severe complications or NICU admission. These findings highlight the importance of appropriate comparator selection to minimize confounding and illustrate how target trial emulation can improve causal inference in studies of medication safety during pregnancy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.22790","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:30:20Z","timestamp":1783956620000},"page":"e2622790","source":"Crossref","is-referenced-by-count":0,"title":["Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy"],"prefix":"10.1001","volume":"9","author":[{"given":"Layla","family":"Aref","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Hughey","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Shirazi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Biodevelopmental Origins of Lung Disease (BOLD) Center, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M. S.","family":"Sucre","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee"},{"name":"Biodevelopmental Origins of Lung Disease (BOLD) Center, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bastarache","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Biodevelopmental Origins of Lung Disease (BOLD) Center, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"4","key":"zoi260638r1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States.","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"zoi260638r2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jad.2025.01.044","article-title":"Inclination of antidepressant medication continuation during pregnancy between 2012 and 2023 in Japan: a cohort study.","volume":"374","author":"Ishikawa","year":"2025","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi260638r3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamapsychiatry.2023.0041","article-title":"Timing of antidepressant discontinuation during pregnancy and postpartum psychiatric outcomes in Denmark and Norway.","volume":"80","author":"Trinh","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"zoi260638r4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2019.12.014","article-title":"The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability.","volume":"264","author":"Molenaar","year":"2020","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi260638r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57324","article-title":"Antidepressant use before, during, and after pregnancy.","volume":"8","author":"Boone","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260638r6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s40262-025-01574-5","article-title":"Prediction of maternal and fetal exposure to escitalopram, sertraline, and paroxetine by combining human ex vivo placenta perfusion data and physiologically based pharmacokinetic modeling.","volume":"64","author":"Pr\u00e9ta","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"zoi260638r7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":"Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"zoi260638r8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.genhosppsych.2009.04.003","article-title":"The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.","volume":"31","author":"Yonkers","year":"2009","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"zoi260638r9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04332.x","article-title":"Prescribing without evidence\u2014pregnancy.","volume":"74","author":"Thomas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"zoi260638r10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/acps.12042","article-title":"Antidepressant use in pregnancy: a critical review focused on risks and controversies.","volume":"127","author":"Byatt","year":"2013","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"zoi260638r11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11920-022-01372-x","article-title":"Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an updated review on risks to mother, fetus, and child.","volume":"24","author":"Lebin","year":"2022","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"zoi260638r12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.","volume":"354","author":"Chambers","year":"2006","journal-title":"N Engl J Med"},{"key":"zoi260638r13","doi-asserted-by":"publisher","first-page":"f6932","DOI":"10.1136\/bmj.f6932","article-title":"Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis.","volume":"348","author":"Grigoriadis","year":"2014","journal-title":"BMJ"},{"issue":"21","key":"zoi260638r14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.","volume":"313","author":"Huybrechts","year":"2015","journal-title":"JAMA"},{"key":"zoi260638r15","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","author":"Hern\u00e1n","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi260638r16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-020-0925-1","article-title":"EHRs could clarify drug safety in pregnant people.","volume":"26","author":"Challa","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"zoi260638r18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"23","key":"zoi260638r19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.21105\/joss.00648","article-title":"comorbidity: an R package for computing comorbidity scores.","volume":"3","author":"Gasparini","year":"2018","journal-title":"J Open Source Softw"},{"issue":"5","key":"zoi260638r20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.5811\/WESTJEM.58408","article-title":"Race, healthcare, and health disparities: a critical review and recommendations for advancing health equity.","volume":"24","author":"Macias-Konstantopoulos","year":"2023","journal-title":"West J Emerg Med"},{"issue":"9","key":"zoi260638r21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"9","key":"zoi260638r22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00228-017-2269-4","article-title":"The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies.","volume":"73","author":"Tak","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi260638r23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jpsychires.2020.02.023","article-title":"Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies.","volume":"124","author":"Biffi","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"9","key":"zoi260638r24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/pds.4242","article-title":"Use of antidepressant medication in pregnancy and adverse neonatal outcomes: a population-based investigation.","volume":"26","author":"Cantarutti","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"zoi260638r25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad655","article-title":"Next-generation phenotyping: introducing phecodeX for enhanced discovery research in medical phenomics.","volume":"39","author":"Shuey","year":"2023","journal-title":"Bioinformatics"},{"key":"zoi260638r26","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23001","article-title":"Using ICD-9 codes to establish prevalence of malformations in newborn infants.","author":"Holmes","journal-title":"Birth Defects Res Part A: Clin Molec Teratol"},{"key":"zoi260638r27","doi-asserted-by":"publisher","DOI":"10.32614\/RJ-2022-011","article-title":"PSweight: an R package for propensity score weighting analysis.","author":"Zhou","journal-title":"R J"},{"issue":"5","key":"zoi260638r28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias.","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"issue":"4","key":"zoi260638r29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jamapsychiatry.2013.684","article-title":"Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis.","volume":"70","author":"Ross","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi260638r30","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1176\/appi.ajp.2015.14121575","article-title":"Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: results from population-based national register data.","volume":"172","author":"Malm","year":"2015","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi260638r31","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.4088\/JCP.12r07967","article-title":"The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis.","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi260638r32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/AOG.0000000000000410","article-title":"Depression drug treatment outcomes in pregnancy and the postpartum period: a systematic review and meta-analysis.","volume":"124","author":"McDonagh","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"1","key":"zoi260638r33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13367","article-title":"Neonatal outcome and adaption after in utero exposure to antidepressants: a systematic review and meta-analysis.","volume":"145","author":"Kautzky","year":"2022","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"zoi260638r34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002166","article-title":"Combined use of selective serotonin reuptake inhibitors and sedatives\/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects.","volume":"3","author":"Reis","year":"2013","journal-title":"BMJ Open"},{"issue":"4","key":"zoi260638r35","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.4088\/JCP.12r07966","article-title":"Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence.","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"zoi260638r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116038","article-title":"Prenatal antidepressant use and risk of congenital malformations: a population-based cohort study.","volume":"339","author":"Chan","year":"2024","journal-title":"Psychiatry Res"},{"issue":"12","key":"zoi260638r37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/jamapsychiatry.2020.2453","article-title":"Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects.","volume":"77","author":"Anderson","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi260638r38","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/1471-0528.14144","article-title":"Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.","volume":"123","author":"Eke","year":"2016","journal-title":"BJOG"},{"issue":"11","key":"zoi260638r39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamapsychiatry.2017.2733","article-title":"Association of panic disorder, generalized anxiety disorder, and benzodiazepine treatment during pregnancy with risk of adverse birth outcomes.","volume":"74","author":"Yonkers","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi260638r40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/archdischild-2023-326049","article-title":"Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study.","volume":"109","author":"Cornet","year":"2024","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"zoi260638r41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1037\/ser0000969","article-title":"Assessing availability of depression severity indicators in electronic health record data: a retrospective study in two large academic health care systems in the United States.","volume":"23","author":"Anderson","year":"2026","journal-title":"Psychol Serv"},{"key":"zoi260638r17","unstructured":"EQUATOR Network. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources. Accessed January 9, 2026. https:\/\/www.equator-network.org\/reporting-guidelines\/good-research-practices-for-comparative-effectiveness-research-defining-reporting-and-interpreting-nonrandomized-studies-of-treatment-effects-using-secondary-data-sources-the-ispor-good-research-pr\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851594\/aref_2026_oi_260638_1783366217.34552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:30:21Z","timestamp":1783956621000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.22790","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}